NCT02607631View on ClinicalTrials.gov

A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

August 31, 2018

Conditions
Thymic Epithelial Tumors
Interventions
DRUG

Pembrolizumab

treated with Pembrolizumab 200 mg every 3 weeks

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02607631 - A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor | Biotech Hunter | Biotech Hunter